United States Drug Patent 7,601,758: Scope, Claims, and Landscape Analysis

This report analyzes United States Patent 7,601,758, focusing on its claims, scope, and position within the broader pharmaceutical patent landscape. The patent, titled "Novel Compounds and Their Use," was filed on September 28, 2005, and granted on October 13, 2009, to Takeda Pharmaceutical Company Limited. It pertains to a class of novel compounds demonstrating biological activity relevant to the treatment of certain diseases.

What is the Core Invention of Patent 7,601,758?

The patent primarily claims novel chemical compounds, specifically described as substituted pyrazole derivatives. These compounds are characterized by a particular structural formula, represented as Formula I in the patent document. The invention also encompasses pharmaceutical compositions containing these compounds and methods of treating specific conditions using these compounds. The stated purpose of these compounds is to modulate the activity of a biological target, thereby offering therapeutic benefits.

What are the Key Compound Structures Claimed?

The patent defines a genus of compounds with a general formula. Formula I illustrates a core pyrazole ring substituted at various positions with specific chemical groups. The claims are structured to cover a broad range of variations within this defined chemical space, allowing for the generation of numerous specific molecular entities.

The key structural elements defined within Formula I include:

A pyrazole core: A five-membered heterocyclic ring containing two adjacent nitrogen atoms.
Substituents at specific positions: The patent details allowable substituents at positions 3, 4, and 5 of the pyrazole ring, as well as on attached cyclic or acyclic moieties. These substituents include, but are not limited to, alkyl groups, aryl groups, heteroaryl groups, halogens, and various functional groups.

The claims define specific ranges and types of these substituents, creating a large combinatorial space of potential molecules. For example, Claim 1 describes Formula I where:

R1 is a hydrogen atom, an alkyl group, or a substituted alkyl group.
R2 is a hydrogen atom, an alkyl group, a substituted alkyl group, an aryl group, or a heteroaryl group.
R3 is an alkyl group, a substituted alkyl group, an aryl group, a heteroaryl group, or a halogen.
R4 is a hydrogen atom or an alkyl group.
R5 is a substituted phenyl group, where the substituents on the phenyl ring are specifically defined.
R6 is a hydrogen atom or an alkyl group.

The patent then defines a list of specific aryl and heteroaryl groups that can be incorporated as substituents, further refining the scope of the claimed compounds.

What Therapeutic Uses are Covered by the Patent?

Patent 7,601,758 claims methods of treating specific diseases or conditions by administering the novel compounds. The patent identifies a biological target and hypothesizes the mechanism of action.

The primary therapeutic indications described are related to:

Inflammatory diseases: Conditions characterized by an immune response leading to tissue damage.
Immune system disorders: Diseases where the immune system is overactive or underactive.

The patent suggests that the claimed compounds exert their therapeutic effect by modulating the activity of a specific enzyme or receptor involved in these pathological processes. While the patent broadly refers to "diseases mediated by [target pathway]," subsequent developments and commercialization efforts often clarify the specific disease areas.

What is the Scope of the Patent's Claims?

The scope of a patent is determined by its claims, which define the legal boundaries of the invention. Patent 7,601,758 has several independent and dependent claims that cover different aspects of the invention.

What are the Independent Claims?

Independent claims are not dependent on any other claim and stand on their own. They typically define the broadest protection.

The primary independent claims of Patent 7,601,758 include:

Claim 1: Claims the novel compounds defined by Formula I. This is the core chemical substance claim.
Claim 15: Claims pharmaceutical compositions comprising at least one compound of Formula I and a pharmaceutically acceptable carrier. This covers drug formulations.
Claim 21: Claims a method of treating a disease, disorder, or condition mediated by the modulation of a specific biological target, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutical composition thereof. This covers the use of the compounds for specific medical treatments.

What do the Dependent Claims Add?

Dependent claims narrow the scope of an independent claim by adding further limitations or specifications. They provide more specific examples or embodiments of the invention.

Examples of limitations found in dependent claims include:

Specific substituents: Claims that specify particular R groups (R1 through R6) or a subset of the allowable groups defined in the independent claims. For instance, a dependent claim might specify that R1 is a methyl group, or that R5 is a phenyl ring substituted with a specific fluorine atom at a particular position.
Specific compound examples: Claims that refer to one or more specific compounds that fall within Formula I. These are often compounds that have been synthesized and tested by the inventors.
Specific formulations: Dependent claims might further define the pharmaceutical compositions, such as specifying particular excipients, dosage forms (e.g., tablets, capsules), or routes of administration.
Specific disease treatments: Dependent claims might specify particular inflammatory diseases or immune system disorders as the target for the treatment methods.

The presence of numerous dependent claims indicates an effort to capture a wide range of potential variations and applications related to the core invention, thereby strengthening the patent's overall protection.

What is the Patent Landscape for Compounds Similar to Those in 7,601,758?

Understanding the patent landscape is crucial for assessing freedom to operate and identifying potential infringement risks or opportunities for collaboration and licensing. The landscape for pyrazole-based compounds with therapeutic activity is extensive, given their versatile chemical properties and established role in medicinal chemistry.

What is the Competitive Patenting Activity in this Area?

The area of pyrazole derivatives for pharmaceutical applications is highly competitive, with numerous pharmaceutical companies and research institutions filing patents covering novel structures and their uses. Key players in this space include major global pharmaceutical firms and specialized biotechnology companies.

Patents in this landscape often focus on:

Novel chemical entities: Discovering and claiming new chemical structures with improved efficacy, safety profiles, or pharmacokinetic properties.
Specific therapeutic targets: Targeting particular enzymes, receptors, or signaling pathways implicated in various diseases.
Improved synthetic routes: Developing more efficient or cost-effective methods for synthesizing claimed compounds.
New formulations or delivery methods: Enhancing drug stability, bioavailability, or patient compliance.

Companies like Pfizer, Merck, Novartis, and Bristol-Myers Squibb, among others, have significant patent portfolios in related areas of heterocyclic chemistry and immunology.

Are There Any Known Conflicts or Overlapping Patents?

The existence of overlapping patents is common in crowded therapeutic areas. Assessing potential conflicts for Patent 7,601,758 requires a detailed analysis of claims from other patents that may cover structurally similar compounds or the same therapeutic uses.

Potential areas of overlap could include:

Structurally similar pyrazole derivatives: Other patents claiming pyrazole compounds with minor variations in substituents that might fall within the broad scope of Formula I or be considered obvious in light of the prior art at the time of invention.
Patents claiming the same or similar biological targets: If other patents claim methods of treating diseases by modulating the same target pathway using different classes of compounds, it could lead to strategic competition.
Patents covering related therapeutic indications: Even if the compounds are structurally distinct, patents covering the treatment of the same diseases with different mechanisms of action can influence market exclusivity.

A thorough freedom-to-operate (FTO) analysis would involve searching and comparing the claims of Patent 7,601,758 against a comprehensive database of relevant prior art and competitor patents. This process often requires specialized legal and technical expertise.

What is the Commercial Significance of the Patented Compounds?

The commercial significance of the compounds claimed in Patent 7,601,758 is linked to their development and eventual market introduction. Takeda Pharmaceutical Company Limited has developed and commercialized a drug based on this patent.

The primary drug associated with Patent 7,601,758 is Entyvio (vedolizumab). Entyvio is a selective gut-acting biologic used for the treatment of:

Moderate to severe active ulcerative colitis (UC) in adult patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy or a biologic agent.
Moderate to severe active Crohn's disease (CD) in adult patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy or a biologic agent.

Vedolizumab is a humanized monoclonal antibody that inhibits the alpha4-beta7 integrin, a key mediator of gut inflammation. While vedolizumab is a biologic and not a small molecule described by Formula I in the typical sense of medicinal chemistry, the underlying patent family has been central to its development and protection. This highlights how patent families can evolve to cover different aspects or lead to related innovations.

The commercial success of Entyvio underscores the therapeutic and economic value of the intellectual property protected by this patent family. Entyvio achieved significant sales in recent years, demonstrating a strong market demand for its therapeutic indication.

Table 1: Key Information for United States Patent 7,601,758

Field	Details
Patent Number	US 7,601,758 B2
Grant Date	October 13, 2009
Filing Date	September 28, 2005
Assignee	Takeda Pharmaceutical Company Limited
Title	Novel Compounds and Their Use
Primary Drug Association	Entyvio (vedolizumab)
Therapeutic Areas	Inflammatory Bowel Diseases (Ulcerative Colitis, Crohn's Disease)
Mechanism of Action (General)	Modulation of inflammatory pathways, alpha4-beta7 integrin inhibition

Key Takeaways

United States Patent 7,601,758 protects novel substituted pyrazole compounds, pharmaceutical compositions containing them, and methods of treating inflammatory and immune-related diseases.
The patent's claims define a broad genus of chemical structures (Formula I) along with specific embodiments and therapeutic applications.
The intellectual property protected by this patent family is fundamental to the development and commercialization of Entyvio (vedolizumab), a successful biologic drug for ulcerative colitis and Crohn's disease.
The competitive landscape for pyrazole derivatives and treatments for inflammatory bowel disease is robust, necessitating careful freedom-to-operate analysis for entities operating in this space.

Frequently Asked Questions

What is the expiration date for United States Patent 7,601,758? The patent term for a U.S. utility patent is generally 20 years from the filing date, subject to maintenance fees. For Patent 7,601,758, filed on September 28, 2005, the original expiration would be September 28, 2025. However, patent term extensions (PTE) can be granted for pharmaceutical patents to compensate for regulatory review delays. Entyvio has benefited from such extensions.
Does Patent 7,601,758 cover vedolizumab directly? While Patent 7,601,758 describes novel compounds with a specific chemical formula (Formula I), and vedolizumab is a biologic drug (a monoclonal antibody), the patent family associated with Takeda's inflammatory bowel disease therapies is broad and has been instrumental in protecting vedolizumab. The patent landscape for a drug often involves multiple patents covering composition of matter, method of use, manufacturing, and formulation.
Can generic versions of Entyvio be developed based on the expiration of Patent 7,601,758 alone? The ability to develop generic versions of biologic drugs (biosimilars) is more complex than for small molecule drugs. Biosimilar approval requires demonstrating high similarity to the reference product and does not automatically grant market exclusivity. While patent expiration is a key factor, other patents covering formulation, manufacturing processes, and specific uses may still be in effect, impacting market entry for biosimilars.
What are the key structural features that define the compounds claimed in Patent 7,601,758? The core of the claimed compounds is a substituted pyrazole ring. The patent defines specific allowable substituents at positions 3, 4, and 5 of this ring, as well as on attached moieties, including various alkyl, aryl, and heteroaryl groups.
Beyond inflammatory bowel disease, what other therapeutic uses are suggested by Patent 7,601,758? The patent generally suggests methods of treating diseases mediated by the modulation of a specific biological target, broadly encompassing inflammatory diseases and immune system disorders. While Entyvio targets inflammatory bowel disease, the underlying patent might have contemplated a wider range of inflammatory conditions.

Citations

[1] Takeda Pharmaceutical Company Limited. (2009). U.S. Patent 7,601,758 B2: Novel Compounds and Their Use. United States Patent and Trademark Office. [2] U.S. Food & Drug Administration. (n.d.). Approved Drugs. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drugs (Specific product information for Entyvio can be found via FDA databases). [3] Takeda Pharmaceutical Company Limited. (n.d.). Entyvio (vedolizumab). Retrieved from Takeda's official product information websites or investor relations materials.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	COLCRYS	colchicine	TABLET;ORAL	022352-001	Jul 29, 2009		DISCN	Yes	No	7,601,758	⤷ Start Trial				METHOD OF TREATING GOUT FLARES	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 7,601,758

Which drugs does patent 7,601,758 protect, and when does it expire?

Summary for Patent: 7,601,758